After years of debate, the Food and Drug Administration has withdrawn a rule that would have allowed generic drug makers to unilaterally update their product labeling when they learn of new information.

In explaining its reasons, the agency worried the rule could create “unintended consequences” by confusing patients and doctors if some generic companies did not revise labeling on a timely basis, or if generic and brand labels appeared different. FDA officials also pointed to concerns expressed by generic makers that they would have to raise prices to cover added costs for complying with the rule.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • let’s be clear – this isn’t about ALLOWING generics manufacturers to update the labels of the drugs they sell, they’re complaining because the regulation would COMPEL them to.
    Making the original company responsible when the brand has lost patent protection and so they’ve lost essentially all profit on that product seems unfair at best and frankly irrational. Once generics companies are making all the $ on a drug (and let’s be clear, on many of these generics they’re making tens of millions per year), they should bear responsibility, in concert with the FDA, to adjust labels as new data (usually safety) becomes known. The generic company’s complaint is essentially that this is a cost that cuts into their profits. Patient safety and prescriber confusion arguments are obfuscation, pure and simple.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy